Challenges in therapeutic glycoprotein production

Current Opinion in Biotechnology

Volumn 17, Issue 4, 2006, Pages 341-346

  Sethuraman, Natarajan ^a   Stadheim, Terrance A ^a  

^a GlycoFi Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DRUG PRODUCTS; MONOCLONAL ANTIBODIES; PLANTS (BOTANY); YEAST;

GLYCOPROTEINS; GLYCOSYLATION; MAMMALIAN CELL CULTURE; PROTEIN-BASED DRUGS;

PROTEINS;

ANTIBODY; CARBOHYDRATE BINDING PROTEIN; CARBOHYDRATE DERIVATIVE; ERYTHROPOIETIN; GLUCOSE DERIVATIVE; GLUCOSYLCERAMIDASE; GLYCAN; GLYCOPROTEIN; IMMUNOGLOBULIN G; INTERFERON; MANNOSE BINDING LECTIN; OLIGOSACCHARIDE; PAUCIMANNOSE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALLERGY; ANAPHYLAXIS; ANIMAL CELL CULTURE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOLOGICAL ACTIVITY; CHO CELL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; EXPRESSION VECTOR; GAUCHER DISEASE; GLYCOSYLATION; HEPATITIS C; HUMAN; IMMUNOGENICITY; INSECT CELL CULTURE; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; TRANSGENIC ANIMAL; YEAST;

ANIMALS; BIOTECHNOLOGY; GENE EXPRESSION; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; PLANTS, GENETICALLY MODIFIED; POLYSACCHARIDES; RECOMBINANT PROTEINS;

INSECTA; MAMMALIA;

EID: 33746750608     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2006.06.010     Document Type: Review

References (47)

1. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol 23 (2005) 553-558
2. LaTemple D.C., Abrams J.T., Zhang S.Y., and Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for α1,3galactosyltransferase. Cancer Res 59 (1999) 3417-3423
3. Galili U., Rachmilewitz E.A., Peleg A., and Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 160 (1984) 1519-1531
4. Bardor M., Faveeuw C., Fitchette A.C., Gilbert D., Galas L., Trottein F., Faye L., and Lerouge P. Immunoreactivity in mammals of two typical plant glyco-epitopes, core α(1,3)-fucose and core xylose. Glycobiology 13 (2003) 427-434. This report discusses the presence of the non-human core xylose and α-1,3-fucose N-linked glycoforms on proteins expressed in plants. The authors demonstrate the existence of IgG1/IgM antibodies toward plant glyco-epitopes in healthy non-allergic blood donors.
5. Gomord V., and Faye L. Post-translational modification of therapeutic proteins in plants. Curr Opin Plant Biol 7 (2004) 171-181
6. Macdougall I.C. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 17 Suppl 5 (2002) 66-70
7. Fukuda M.N., Sasaki H., Lopez L., and Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73 (1989) 84-89
8. Stockert R.J. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 75 (1995) 591-609
9. Maynard Y., and Baenziger J.U. Oligosaccharide specific endocytosis by isolated rat hepatic reticuloendothelial cells. J Biol Chem 256 (1981) 8063-8068
10. Lai P.H., Everett R., Wang F.F., Arakawa T., and Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem 261 (1986) 3116-3121
11. Higuchi M., Oh-eda M., Kuboniwa H., Tomonoh K., Shimonaka Y., and Ochi N. Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem 267 (1992) 7703-7709
12. Dordal M.S., Wang F.F., and Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 116 (1985) 2293-2299
13. Yuen C.T., Storring P.L., Tiplady R.J., Izquierdo M., Wait R., Gee C.K., Gerson P., Lloyd P., and Cremata J.A. Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Br J Haematol 121 (2003) 511-526. Process-dependent changes in N-linked glycosylation of human EPO produced in CHO cells are described. These changes are shown to affect the biological activity of EPO with enrichment of tetraantennary sialylated EPO having the greatest potency.
14. Elliott S., Egrie J., Browne J., Lorenzini T., Busse L., Rogers N., and Ponting I. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32 (2004) 1146-1155
15. Egrie J.C., and Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 Suppl 3 (2001) 3-13
16. Friedman B., Vaddi K., Preston C., Mahon E., Cataldo J.R., and McPherson J.M. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood 93 (1999) 2807-2816
17. Festi D., Sandri L., Mazzella G., Roda E., Sacco T., Staniscia T., Capodicasa S., Vestito A., and Colecchia A. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 10 (2004) 12-16
18. Rothman R.J., Perussia B., Herlyn D., and Warren L. Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation. Mol Immunol 26 (1989) 1113-1123
19. Irie A., Koyama S., Kozutsumi Y., Kawasaki T., and Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 273 (1998) 15866-15871
20. Zhu A., and Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9 (2002) 376-381
21. Fukuta K., Yokomatsu T., Abe R., Asanagi M., and Makino T. Genetic engineering of CHO cells producing human interferon-γ by transfection of sialyltransferases. Glycoconj J 17 (2000) 895-904
22. Fukuta K., Abe R., Yokomatsu T., Kono N., Asanagi M., Omae F., Minowa M.T., Takeuchi M., and Makino T. Remodeling of sugar chain structures of human interferon-γ. Glycobiology 10 (2000) 421-430
23. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity. J Biol Chem 277 (2002) 26733-26740
24. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17 (1999) 176-180
25. Hamilton S.R., Bobrowicz P., Bobrowicz B., Davidson R.C., Li H., Mitchell T., Nett J.H., Rausch S., Stadheim T.A., Wischnewski H., et al. Production of complex human glycoproteins in yeast. Science 301 (2003) 1244-1246. The first demonstration of the production of protein in yeast harboring human complex N-glycosylation is described. Human N-glycosylation pathway engineering expands the role of yeast for the production of therapeutic glycoproteins.
26. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., Wakitani M., Niwa R., Sakurada M., Uchida K., et al. Establishment of FUT8 knockout chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87 (2004) 614-622
27. Kost T.A., Condreay J.P., and Jarvis D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 23 (2005) 567-575
28. Liang M., Guttieri M., Lundkvist A., and Schmaljohn C. Baculovirus expression of a human G2-specific, neutralizing IgG monoclonal antibody to puumala virus. Virology 235 (1997) 252-260
29. zu Putlitz J., Kubasek W.L., Duchene M., Marget M., von Specht B.U., and Domdey H. Antibody production in baculovirus-infected insect cells. Biotechnology (NY) 8 (1990) 651-654
30. Hasemann C.A., and Capra J.D. High-level production of a functional immunoglobulin heterodimer in a baculovirus expression system. Proc Natl Acad Sci USA 87 (1990) 3942-3946
31. Li H., Sethuraman N., Stadheim T.A., Zha D., Prinz B., Ballew N., Bobrowicz P., Choi B.K., Cook W.J., Cukan M., et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24 (2006) 210-215. This report describes the expression of IgG1 with human N-glycosylation in yeast. IgG1 antibodies produced by this expression system demonstrate >100-fold enhanced receptor binding and increased in vitro B-cell depletion activity compared with a matched CHO-produced IgG1.
32. Kim Y.K., Shin H.S., Tomiya N., Lee Y.C., Betenbaugh M.J., and Cha H.J. Production and N-glycan analysis of secreted human erythropoietin glycoprotein in stably transfected drosophila S2 cells. Biotechnol Bioeng 92 (2005) 452-461. The expression and secretion of human EPO from S2 insect cells is reported. EPO expressed in S2 insect cells displays a mixture of terminal mannose and N-acetylglucosamine human N-glycan intermediates.
33. Garcia-Casado G., Sanchez-Monge R., Chrispeels M.J., Armentia A., Salcedo G., and Gomez L. Role of complex asparagine-linked glycans in the allergenicity of plant glycoproteins. Glycobiology 6 (1996) 471-477
34. Legardinier S., Klett D., Poirier J.C., Combarnous Y., and Cahoreau C. Mammalian-like nonsialyl complex-type N-glycosylation of equine gonadotropins in mimic insect cells. Glycobiology 15 (2005) 776-790
35. Giddings G., Allison G., Brooks D., and Carter A. Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol 18 (2000) 1151-1155
36. Bakker H., Bardor M., Molthoff J.W., Gomord V., Elbers I., Stevens L.H., Jordi W., Lommen A., Faye L., Lerouge P., et al. Galactose-extended glycans of antibodies produced by transgenic plants. Proc Natl Acad Sci USA 98 (2001) 2899-2904
37. Misaki R., Fujiyama K., and Seki T. Expression of human CMP-N-acetylneuraminic acid synthetase and CMP-sialic acid transporter in tobacco suspension-cultured cell. Biochem Biophys Res Commun 339 (2006) 1184-1189. This report demonstrates the introduction of a CMP-sialic acid synthesis pathway in tobacco plant cells. Further engineering of this cell line could offer the expression of proteins with mammalian-like N-glycosylation.
38. Strasser R., Altmann F., Mach L., Glossl J., and Steinkellner H. Generation of Arabidopsis thaliana plants with complex N-glycans lacking β1,2-linked xylose and core α1,3-linked fucose. FEBS Lett 561 (2004) 132-136
39. Houdebine L.M. Antibody manufacture in transgenic animals and comparisons with other systems. Curr Opin Biotechnol 13 (2002) 625-629
40. van Berkel P.H., Welling M.M., Geerts M., van Veen H.A., Ravensbergen B., Salaheddine M., Pauwels E.K., Pieper F., Nuijens J.H., and Nibbering P.H. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol 20 (2002) 484-487
41. Zhu L., van de Lavoir M.C., Albanese J., Beenhouwer D.O., Cardarelli P.M., Cuison S., Deng D.F., Deshpande S., Diamond J.H., Green L., et al. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol 23 (2005) 1159-1169. The expression of human monoclonal antibodies (mAbs) in chicken eggs is reported. This report shows that mAbs produced in chicken eggs display similar antigen binding and antigen-mediated internalization, enhanced ADCC, but increased clearance compared with the CHO-produced mAbs.
42. Cereghino J.L., and Cregg J.M. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev 24 (2000) 45-66
43. Gerngross T.U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22 (2004) 1409-1414
44. Choi B.K., Bobrowicz P., Davidson R.C., Hamilton S.R., Kung D.H., Li H., Miele R.G., Nett J.H., Wildt S., and Gerngross T.U. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc Natl Acad Sci USA 100 (2003) 5022-5027. The production of a glycoprotein with human hybrid N-glycosylation in yeast is described. Also described is a high-throughput screening method for the selection of yeast clones with uniform hybrid N-glycosylation.
45. Bobrowicz P., Davidson R.C., Li H., Potgieter T.I., Nett J.H., Hamilton S.R., Stadheim T.A., Miele R.G., Bobrowicz B., Mitchell T., et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology 14 (2004) 757-766
46. Wildt S., and Gerngross T.U. The humanization of N-glycosylation pathways in yeast. Nat Rev Microbiol 3 (2005) 119-128
47. Wang X., Zhu C., Wang X., Gerwien J.G., Schrattenholz A., Sandberg M., Leist M., and Blomgren K. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 91 (2004) 900-910